Supplementary methods

Cytogenetic and molecular analysis of patient samples
Cases were screened for high hyperdiploidy (51-65 chromosomes), ETV6-RUNX1 and BCR-ABL1 fusion products and rearrangements of TCF3 and MLL by routine diagnostic procedures. Cases in the discovery cohort were identified as BCR-ABL1-like, based on a previously described expression signature of 110 probe sets. 1, 2 The multiplex ligationdependent probe amplification assay SALSA MLPA P335 ALL-IKZF1 (MRC-Holland, Amsterdam, the Netherlands) was performed according to the manufacturer's protocol and analyzed as previously described. 1 A ratio lower than 0.75 for the exon intensity in patients versus the healthy control reference was considered to represent a deletion. For scoring CDKN2A/B deletion, it was sufficient to have either CDKN2A or CDKN2B deleted. Mutation status for IKZF1 was neither assessed in discovery (n=533) nor validation (n=515) cohort.
Flow cytometric analysis
Murine bone marrow (BM) cells were harvested by flushing femurs with RPMI medium (Gibco//Life technologies Europe BV, Bleiswijk, The Netherlands) containing 10% FBS (Greiner Bio-One BV, Alphen a/d Rijn, The Netherlands) and 50μM β-Mercaptoethanol (Gibco). Cells from spleen and thymus were isolated through a 70μM filter using RPMI medium containing 10% FBS and 50μM β-Mercaptoethanol. Leukemic blasts isolated from either lymph nodes, spleen or thymus were analyzed by FACS using the LSRII flow cytometer (BD Biosciences, Breda, The Netherlands). Single cell suspensions were treated with red blood cell lysis buffer (Sigma-Aldrich, Zwijndrecht, The Netherlands ) and preincubated with unlabeled anti-Fc III/II receptor (2.4G2) (BD Biosciences) to inhibit unspecific antibody binding. Cells were stained with the following antibodies purchased from BD Biosciences (Franklin Lakes, New Jersey) and eBiosciences (Vienna, Austria): anti-B220/CD45R (RA3-6B2); BP1 (6C3); CD4 (RM4-5); CD8 (53-6.7); CD11b/Mac1 (M1/70); CD24/HSA (M1/69); CD25 (PC61.5); CD43 (S7); CD44 (IM7); IgM (II/41); IgD (11-26c). The data were collected and analyzed by FlowJo V10 software (FlowJo, Ashland, Oregon).
Immunohistochemistry
Tissues isolated from diseased mice were fixed in 4% formalin for 24 hours. Specimens were embedded in paraffin, 4 µM serial sections were prepared and stained with hematoxylin and eosin (HE). For immunohistochemistry, slides were dewaxed and rehydrated prior to heatinduced antigen retrieval using sodium citrate buffer. After blocking with 2% goat serum and 2% BSA in 0.05% Tween-PBS, the slides were incubated overnight with B220/CD45R (RM2600) (Invitrogen, Amsterdam, The Netherlands) and CD3 (A0452) (DAKO Netherlands BV, Heverlee, Belgium) antibodies. Biotinylated anti-rat IgG (BA9401) (Vector Laboratories, Peterborough, United Kingdom) and anti-rabbit IgG (BA1000) (Vector Laboratories) were used as secondary antibody and subsequently the slides were incubated with metalenhanced diaminobenzidine in stable peroxide substrate buffer (Thermo Fisher Scientific Inc., Amsterdam, The Netherlands), counterstained with hematoxylin, and after dehydration coverslipped with Entellan. Four selected regions per murine liver or lung histological slide were used for the quantification of CD3 + positively stained areas. The analysis was performed with FIJI software. 3 For the quantification of the blood smears, 10 visual fields with a 40x objective were scored for the number of blasts. In total, 10 visual fields per blood smear were averaged and for each genotype the percentage of blasts was determined for three independent mice.
VDJ rearrangement analysis
DNA was extracted from enlarged spleen or lymph nodes using the Gentra Puregene Mouse Tail kit (Qiagen, Venlo, The Netherlands). PCR analysis was performed with primers specific for the DB1-JB region of Trb1, Dβ2.1-Jβ2.7 region of Trb2, and 5'VH2-3'Cµ and 5'VH2-3'C primers for the Igh and Igk genes, respectively ( Supplementary Table S1 ).
Viability assays on murine splenic B-cells
Spleens from healthy young (6-12 weeks of age) wild-type, Ikzf1 +/-, Btg1 -/and Btg1 -/-;Ikzf1 +/mice were isolated and single mononuclear cells were harvested through a 70 µM cell strainer. Erythrocytes within the cell suspensions were removed by Red blood cell lysis buffer (Sigma-Aldrich, Zwijndrecht, The Netherlands). Next, splenocytes were cultured for 48 hours in RPMI 1640 medium (Life technologies, Carlsbad, CA) supplemented with 10% heatinactivated fetal calf serum (FCS), 1% penicillin/streptomycin (Invitrogen), and 50 µM β -Mercaptoethanol in the presence of 5 µg/mL lipopolysaccharide (LPS). Subsequently, splenic B-lymphocytes obtained after ficoll gradient were cultured in a 96-well plate at a density of 1x 10 5 cells/well in the presence of 5 µg/mL LPS. Splenic B-cells were treated with increasing concentrations of prednisolone or dexamethasone (both Centrafarm, Etten-Leur, the Netherlands). After 48 hours, relative cell viability was assessed using the CellTiter 2 96® Supplementary Table S1 . Oligonucleotide primers used for genotyping and IG/TR clonality analysis.
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